Patent ID: 8029788

Claim:
A method for treating cancer in a subject, wherein the cells of the cancer express TAG-72, comprising: administering to the subject an effective amount of a humanized anti-TAG-72 antibody comprising: a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3, wherein L-CDR3, H-CDR1, H-CDR2 and H-CDR3 comprise parental HuCC49 antibody L-CDR3 (SEQ ID NO: 3), H-CDR1 (SEQ ID NO: 4), H-CDR2 (SEQ ID NO: 5) and H-CDR3 (SEQ ID NO: 6), respectively, and wherein (i) L-CDR1 and L-CDR2 comprise human monoclonal LEN antibody L-CDR1 (SEQ ID NO: 7) and L-CDR2 (SEQ ID NO: 8), respectively, (ii) L-CDR1 comprises a human monoclonal LEN antibody L-CDR1 (SEQ ID NO: 7) and L-CDR2 comprises a parental HuCC49 antibody L-CDR2 (SEQ ID NO: 2), or (iii) L-CDR1 comprises a parental HuCC49 antibody L-CDR1 (SEQ ID NO: 1) and L-CDR2 comprises a human LEN antibody L-CDR2 (SEQ ID NO: 8), and wherein the humanized anti-TAG-72 antibody retains binding affinity for TAG-72 and has reduced immunogenicity, as compared to the parental HuCC49 antibody, thereby treating the cancer in the subject.